The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
Vermilion Life Sciences works to Reengineer Medicines Development to reduce development times and costs, speed adoption of new technologies and improve the value of new medicines. Facilitating partnerships between patients, industry, regulators and payers can make medicines available more quickly, at lower cost with greater certainty in use.
We consult on strategic portfolio reviews, clinical strategies and organisational design to enable sponsors to improve their development efficiency and effectiveness.